Observational study on women with Cystic Fibrosis treated with CFTR modulators during pregnancy and postpartum and their children. Registration on maternal health parameters and effects of CFTR-modulators in the newborn infant as well as effects of exposure through mother's own milk.

Start Date15 Mar 2024

Sponsor / Collaborator

Region Stockholm

[+1]

NCT06154447

/ RecruitingPhase 1

A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis

The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).

Start Date12 Dec 2023

Sponsor / Collaborator

Vertex Pharmaceuticals, Inc.

NCT05822102

/ Enrolling by invitationNot ApplicableIIT

Simultaneous quanTification of Elexacaftor/tezAcaftor/Ivacaftor Via Reverse Phase High Performance liquiD chromatographY

The purpose of this study is to support the clinical validation of a new assay to measure the levels of ivacaftor, tezacaftor, and elexacaftor (the components of Trikafta) in the bloodstream in order to achieve greater understanding of the effectiveness of this medication in all people with cystic fibrosis. Blood will be drawn at 3.0, 4.5, and 6.0 hours after taking the medication in the morning.

Start Date09 Feb 2023

Sponsor / Collaborator

National Jewish Health, Inc.

100 Clinical Results associated with Tezacaftor

100 Translational Medicine associated with Tezacaftor

100 Patents (Medical) associated with Tezacaftor

1,067

Literatures (Medical) associated with Tezacaftor

01 Jun 2026·CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications

Review

Author: Owens, Katie ; Argon, Sophie ; Yu, Jingjing ; Ragueneau-Majlessi, Isabelle ; Wang, Yan

Objective:

This analysis aimed to provide a mechanistic understanding and an evaluation of the clinical relevance of pharmacokinetic drug-drug interactions (DDIs) associated with drugs approved by the Food and Drug Administration in 2024.

Methods:

Drug metabolism, transport, and absorption-based DDI data available in New Drug Applications (NDAs) of small molecular drugs approved (n = 34) was analyzed. The mechanism and clinical outcome of these interactions were characterized based on in vitro, in silico, and clinical data.

Results:

As objects, 11 drugs were identified as clinical substrates. Of these, 7 drugs were substrates of CYP3A, 3 of CYP2C9, one of CYP1A2, and one of CYP2C8, including the sensitive substrates vanzacaftor (CYP3A) and vorasidenib (CYP1A2). As precipitants, 6 drugs (acoramidis, cefepime/enmetazobactam, givinostat, lazertinib, mavorixafor, and resmetirom) were clinical inhibitors of CYP enzymes (2C8, 2C9, 2D6, 2E1, and 3A), with mavorixafor being a CYP2D6 strong inhibitor. Two drugs (elafibranor and tovorafenib) showed weak induction of CYP3A. Regarding transporter data, 3 drugs were substrates of transporters, including seladelpar (BCRP and OAT3), sulopenem (OAT3), and vadadustat (OAT1/3), and 8 drugs (arimoclomol, danicopan, givinostat, lazertinib, mavorixafor, resmetirom, vadadustat, and vazacaftor/tezacaftor/deutivacaftor) were inhibitors of transporters. All clinical DDIs with AUC changes ≥ 2-fold triggered labeling recommendations. Several DDIs with an AUC change <2 also had labeling recommendations, pertaining most often to the concomitant use of drugs with a narrow therapeutic index.

Conclusions:

Mechanistic DDI insights from newly approved therapies can be extrapolated to inform the management of commonly co-administered drugs, supporting a safer and more effective use of new drug products in the context of polypharmacy.

01 May 2026·Respiratory Medicine and Research

Skin side-effects of elexacaftor-tezacaftor-ivacaftor: a real-world view

Article

Author: Sunil, Devika ; Phillips, Mirain ; Darby, Alice ; Constantinou, Sophie ; Webber, Lucy ; Goodwin, Richard ; Duckers, Jamie

BACKGROUND:

Since 2020, ETI (elexacaftor/tezacaftor/ivacaftor) has been used to treat patients with cystic fibrosis. Acne and rash are listed as "common" and "very common" adverse effects in the Summary of Product Characteristics for ETI, affecting between 2-5% and 10% of patients respectively. Patients have, however, shared their experience of developing acne and rashes with clinicians and on social media. This study aimed to describe the real-world impact of rash and acne amongst patients taking ETI and to evaluate the service provided by healthcare practitioners.

METHODS:

A paper and/or electronic survey was distributed to adult patients taking ETI in two regional CF centres between November 2022 and February 2023.

RESULTS:

Of the 268 survey respondents, 20.9% reported new-onset acne and 13.8% reported a rash following the commencement of ETI. 11.9% had a past history of acne and reported an exacerbation/recurrence after starting ETI. ETI-associated acne occurred weeks to months after commencement of ETI, whereas most rashes occurred within the first 2 weeks of treatment. Reassuringly for 2/3 of affected patients, acne and rashes were minor side effects, although 1/3 experienced a greater impact on their quality of life.

CONCLUSION:

This study is the first to specifically report the real-world prevalence of acne and rashes amongst patients taking ETI, which is higher than that reported in clinical trials. These findings could be used to improve counselling of patients commencing ETI. Ensuring access to up-to-date resources and treatments for patients experiencing skin side-effects would be mutually beneficial for both patients and healthcare professionals.

01 Mar 2026·ACTA PSYCHOLOGICA

Divergent neurobehavioral effects of CFTR modulators elexacaftor and ivacaftor in mice

Article

Author: Du, Jianyang ; Lu, Hui ; Reznikov, Leah R ; Fagan, Amy ; Ge, Qian

Recent advances in cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination therapies have markedly improved survival and quality of life for people with cystic fibrosis (CF). Among these, the elexacaftor-tezacaftor-ivacaftor combination (Trikafta) and vanzacaftor-tezacaftor-deutivacaftor (Alyftrek), represent major therapeutic milestones. However, emerging reports suggest that Trikafta may contribute to anxiety and depression in some people with CF. In this study, we investigated the neurobehavioral effects of elexacaftor and ivacaftor in mice. Acute administration of elexacaftor elicited anxiety-like behavior, while ivacaftor induced depressive-like behavior. Additionally, we confirmed the presence of Cftr mRNA in the amygdala and hippocampus, brain regions implicated in anxiety and depression. These findings provide preclinical support for the reported mental health side effects experienced by some people with CF and offer new insights into CFTR function within the central nervous system, potentially guiding the development of future CF therapies with improved neuropsychiatric profiles.

142

News (Medical) associated with Tezacaftor

01 Dec 2025

·www.prnewswire.com

Cystic Fibrosis Therapeutics Market Set to Reach USD 35.09 Billion by 2033 as Precision CFTR Modulator Therapies Transform Patient Outcomes

AUSTIN, Texas and TOKYO, Dec. 1, 2025 /PRNewswire/ -- According to DataM Intelligence, the Cystic Fibrosis (CF) Therapeutics Market Size accelerated to USD 10.60 billion in 2024, up from USD 9.22 billion in 2023, and is now projected to expand aggressively to USD 35.09 billion by 2033, recording a CAGR of 14.2% during 2025–2033. The surge is driven by transformational advancements in CFTR modulator therapies, higher treatment access across the U.S. and Europe, the expansion of personalized medicine programs, improvements in newborn screening, and stronger R&D investments targeting rare genetic diseases. Cystic fibrosis, a life-long autosomal recessive disorder caused by mutations in the CFTR gene, affects more than 162,000 patients globally, with rising diagnostic rates enabling broader therapeutic adoption. The past five years have shifted the market from symptomatic management to disease-modifying treatments, marking the most significant clinical progress in CF care in decades. Download PDF Brochure: Browse in-depth TOC on "Cystic Fibrosis Therapeutics Market" 71 – Tables 67 – Figures 192 – Pages Precision Medicine, Breakthrough Modulators & Improved Survival Rates Accelerate Market Adoption Cystic fibrosis has moved from a once-fatal childhood disease to a highly treatable chronic condition, thanks to advanced therapeutic classes. Today's market growth is being propelled by three major dynamics: 1. CFTR Modulator Innovations Are Reshaping the Standard of Care CFTR modulators such as ivacaftor, tezacaftor, elexacaftor, and combination regimens have expanded eligibility to nearly 90% of CF patients, dramatically improving lung function, BMI, respiratory exacerbation rates, and life expectancy. 2. Rising Diagnosis Rates and Earlier Intervention With neonatal screening improving globally, early treatment initiation is raising adherence and increasing long-term therapeutic demand. Countries in Europe and Asia have expanded newborn testing coverage by 12–20% YoY. 3. Growth of Symptom-Relief Therapies in Untreated CFTR Mutations A subset of patients still relies on mucolytics, bronchodilators, pancreatic enzyme replacement, and inhaled antibiotics-ensuring sustained demand across legacy CF drug segments. Market Segmentation: By Drug Class (CFTR Modulators, Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, Others) CFTR Modulators CFTR modulators represented the dominant segment in 2024, accounting for nearly 72% of total revenue (USD 7.63 billion). This class continues to see explosive uptake because of its disease-modifying capabilities and expanded label approvals across adolescents and pediatric patients. Pancreatic Enzyme Supplements Pancreatic enzyme replacement therapies (PERT) accounted for 11% (USD 1.17 billion). They remain standard-of-care for >80% of CF patients due to chronic exocrine pancreatic insufficiency. Mucolytics Mucolytics contributed 8% (USD 848 million), driven by the sustained use of inhaled agents such as dornase alfa for airway clearance. By Route of Administration (Oral, Inhaled, Parenteral) Oral Oral therapies held 69% (USD 7.31 billion) due to the dominance of oral CFTR modulators. This segment will grow fastest through 2033 driven by life-long use and expanded mutation coverage. Inhaled Inhaled therapies contributed 26% (USD 2.76 billion). This includes inhaled mucolytics, bronchodilators, antibiotics, and other respiratory-support agents still widely used in multidisciplinary CF care. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Hospital Pharmacies Hospital pharmacies captured 58% (USD 6.15 billion) as CF remains primarily managed through specialty centers that coordinate multidisciplinary treatment plans. Retail Pharmacies Retail pharmacies represented 31% (USD 3.28 billion), largely driven by the growth of chronic outpatient CF management and expanded insurance coverage. Online Pharmacies Online pharmacies accounted for 11% (USD 1.17 billion) and are increasing rapidly due to home delivery convenience and improved digital prescription services for chronic diseases. Buy This Report with Year-End Offer ( Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): Regional Outlook: United States: Largest and Fastest-Expanding CF Therapeutics Market The U.S. accounted for 54% of global CF drug sales (USD 5.73 billion in 2024). U.S. Market Highlights CF patient registry size exceeds 40,000, representing 25% of global cases CFTR modulator usage penetration surpasses 88% Government and private insurers expanded coverage for next-generation modulators by 20% YoY CF care center expansions increased pulmonary inpatient capacity by 11% By 2033, the U.S. market is forecast to exceed USD 19 billion. Japan: Rapidly Modernizing CF Treatment Landscape Japan accounted for 6% (USD 636 million) of global value in 2024. Japan Market Dynamics Recent improvements in genetic screening increased CF detection rates by 16% YoY Rising access to imported CFTR modulators and specialty respiratory therapies Hospital-based CF clinics increased multidisciplinary patient management capacity by 14% Japan is on track to surpass USD 2.1 billion by 2033 as availability and early diagnosis improve. Competitive Landscape: Below are revenues and cystic-fibrosis or related respiratory/orphan-drug segment contributions based on public annual reports and investor disclosures. Vertex Pharmaceuticals Incorporated 2023 Revenue: USD 9.87 billion CF Franchise Contribution: > USD 9.3 billion (94% of total company revenue) Vertex is the global leader in CFTR modulators including Trikafta/Kaftrio, Symdeko/Symkevi, and Orkambi. F. Hoffmann-La Roche Ltd 2023 Revenue: USD 66.5 billion Respiratory & Infectious Diseases Portfolio: USD 3.4+ billion Expanding CF pipeline with inhaled and anti-inflammatory therapies. Novartis Pharmaceuticals Corporation 2023 Revenue: USD 45.4 billion Immunology & Respiratory Division: USD 8.1 billion Active in inhaled antibiotic programs and airway clearance technologies. Teva Pharmaceuticals USA, Inc. 2023 Revenue: USD 15.8 billion Respiratory Portfolio Contribution: USD 1.7 billion Strong presence in inhalation therapies supporting CF symptom relief. Gilead Sciences, Inc. 2023 Revenue: USD 27.1 billion Antiviral & Anti-Infective Division: USD 5.8 billion Previously developed Cayston (inhaled aztreonam), widely used for chronic lung infections in CF patients. Buy This Report with Year-End Offer ( Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): The Decade Ahead: What will Define the Future of Cystic Fibrosis Therapeutics The Cystic Fibrosis market is on track for the fastest evolution in its history, driven by: Next-gen CFTR modulators targeting rare mutations Combination RNA therapies for non-responders Gene-editing and gene-replacement programs, particularly using CRISPR Inhaled biologics addressing persistent lung infection Improved lipid nanoparticle (LNP) delivery systems enabling organ-specific targeting Pediatric expansion increasing long-term treatment demand Real-world evidence integration improving precision dosing By 2033, cystic fibrosis care will be defined by personalized molecular therapies, multi-modality regimens, and potentially curative genetic treatments-setting the stage for the CF therapeutics market to become one of the most valuable rare-disease drug markets globally. Related Report: Duchenne Muscular Dystrophy Therapeutics Market Size to Surge from US$2.19 B in 2024 to US$6.64 B by 2033 - 13.2% CAGR. Marfan Syndrome Treatment Market Size to Grow from US$203.5 M in 2023 to US$312.6 M by 2031 - Driven by Rising Diagnosis & Advanced Therapeutic & Surgical Care. Huntington's Disease Market Size to Grow from US$456 M in 2024 to US$3.23 B by 2033 - >7.5% CAGR Signals Surge in Therapeutic & R&D Activity. Sickle Cell Anaemia Testing Market Share to Grow at 12% CAGR - From US$0.43 B in 2024 to Over US$1.5 B by 2032. About DataM Intelligence DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations. To find out more, visit or follow us on Twitter, LinkedIn, and Facebook. Contact: Sai Kiran DataM Intelligence 4market Research LLP Ground floor, DSL Abacus IT Park, Industrial Development Area Uppal, Hyderabad, Telangana 500039 USA: +1 877-441-4866 Email: [email protected] Logo: SOURCE DataM Intelligence 4 Market Research LLP 21% more press release views with Request a Demo

25 Oct 2025

·pharma.economictimes.indiatimes.com

Bangladeshi generic version slashes rare disease drug’s price by 96%

Bangladeshi pharmaceutical company Beximco has launched a generic version of a triple combination therapy for a rare genetic disorder. US-based Vertex, which holds the patent for this therapy, charges $325,300 for a year’s treatment while the generic will slash the price by 96% to just $12,775 for adults and about $6,390 for a child per year. Patients of cystic fibrosis, a rare genetic disorder, and their families launched a community-run buyers’ club on Thursday to help patients around the world access the new generic version of the drug. Vertex’s monopoly is estimated to have generated almost $30 billion in profits over ten years just from the sale of the medicine for cystic fibrosis. A 2022 study on production costs of the medicine estimated that it could be produced for $5,700 per patient per year. Beximco is launching the generic version of the triple combination (elexacaftor, tezacaftor and ivacaftor) listed as an essential medicine by the WHO . It is also launching a generic version of ivacaftor, one of the components, as the treatment consists of two tablets of the triple combination and one tablet of ivacaftor every day for adults. “This is a historic moment. We’ve watched children suffer and die while a treatment sat on the shelf, priced out of reach. Today, that changes. We’ve proven that patient power can change what billion-dollar corporations refuse to. Governments must act fast to take all the necessary steps to make this life saving drug available for every eligible patient,” said Gayle Pledger, who leads the global Right to Breathe campaign, which has been working to make this medicine accessible for cystic fibrosis patients. Cystic fibrosis disrupts mucus production in multiple organs, particularly the lungs and digestive system, leading to debilitating symptoms, such as serious chronic respiratory issues and malnutrition. Delayed diagnosis and lack of treatment contribute to an average life expectancy of less than 20 years. Tanya Takewani, mother of a child in India with cystic fibrosis, pointed out that 14 children died in 2024 waiting for treatment. “This drug has been available for more than six years. How many more children must have died in these years? There are 600 patients of cystic fibrosis identified in India. But only 50 of them get treatment under the Patient Assistance Programme. The development of a generic gives us hope,” said Takewani. Chetali Rao, a scientific researcher with Third World Network (TWN), a nonprofit that has been helping to make medicines accessible, said, “When a medicine costs more than life itself, it stops being an innovation, it becomes an exclusion. Trikafta can transform a life-threatening disease like cystic fibrosis into a manageable condition. It must be available and we were determined to find a way to make it affordable.” This urgency drove TWN, together with patient groups Just Treatment in the UK and Right to Breathe, to approach Beximco with the proposal to develop an affordable generic alternative. By Rema Nagarajan ,

Drug Approval

24 Oct 2025

·www.fiercepharma.com

CF buyers club aims to grow access to Vertex's Trikafta through trade-policy workaround

Trikafta still possesses numerous patent protections around the world, but the buyers club has plotted a workaround by tapping Bangladeshi manufacturer Beximco to produce the generic. To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy Trikafta, a buyers club has resurfaced with a plan to introduce a discounted generic of the drug in certain parts of the world.Under the strategy, the new generic of Trikafta—which combines the CFTR modulator drugs ivacaftor, tezacaftor and elexacaftor—will cost $12,750 a year for adults and $6,375 annually for kids, well below the $370,000 list price the medicine carries in the U.S., the buyers club said in a Thursday press release.Trikafta, which generated full-year sales of $11.02 billion last year, still possesses numerous patent protections around the world. But the buyers club believes it has plotted a workaround by tapping Bangladeshi manufacturer Beximco to produce a generic option.Given its classification as a least developed country (LDC), Bangladesh is not beholden to pharmaceutical patents under the World Trade Organization agreement on trade-related aspects of intellectual property rights (TRIPS). That means Beximco can legally manufacture and export generics of patented drugs, the buyers group explained.As for the potential reach of the Trikafta generic, many countries have legal exemptions in place that allow people to purchase and import medicines for personal use, the group explained, noting that patients, families, doctors and health service employees can now “register their interest” in the cheaper copycat on the buyers club website.The buyers club effort looks poised to predominantly benefit patients in low- and middle-income countries (LMICs) where Trikafta is either cost-prohibitive or unavailable outright. Patients in the U.S., however, are less likely to benefit, given that it is often illegal for people to import drugs into the country for personal use if they haven’t been approved by the FDA.On the other hand, certain countries like the U.K.—where at least one of the organizations behind the buyer's club is based—do allow patients to import certain medicines for personal use, under strict conditions. The generic will carry the name Triko and become available for purchase starting in the spring of 2026, according to the buyers club, which was borne out of the efforts of multiple advocacy and cystic fibrosis (CF) patient groups.Vertex’s pricing and patenting strategy around Trikafta and predecessor CF meds has long been controversial, and the buyers club did not hold back in calling out the company for creating “deep inequality in access to the treatment.” Cystic fibrosis, a progressive, genetic disease of the lungs, pancreas and other organs, is thought to affect more than 188,000 people around the world, the buyers club pointed out, citing a 2024 paper critical of current Trikafta access levels. Among that group, some 60% are diagnosed and just 27% are on treatment for their disease, according to the organization. The Cystic Fibrosis Foundation estimates that around 105,000 people have been diagnosed with CF across 94 countries.Treatment disparities appear rife when looking at LMICs, where researchers last year estimated that around 82% of undiagnosed CF patients live. Meanwhile, just one LMIC reported patient reimbursement for Trikafta, versus 35 high-income countries at the time the paper was written.Vertex, for its part, did not directly respond to Fierce Pharma’s request for comment on the purchasing group’s announcement. Instead, a spokesperson pointed to a “CF facts and figures” page on the company’s website, where Vertex asserts that it is “committed to develop and provide access to our CF medicines to as many eligible people living with CF who can potentially benefit from them.”Vertex contends that its approved modulators are suitable for around 90% of people living with CF and states that its medicines are currently treating more than 75,000 people with CF globally, or about two-thirds of the disease’s diagnosed patient population.The company’s CF drugs are available in over 60 countries, more than 50 of which have secured “broad access agreements,” Vertex notes. Additionally, the company has rolled out a pilot donation program in tandem with the group Direct Relief to provide Trikafta to eligible patients in 14 countries, including Ukraine, Nepal, India, Egypt, Ivory Coast, Sri Lanka and El Salvador.But for the buyers club and advocacy groups behind its access push, those efforts are not enough.“We’ve watched children suffer and die while a treatment sat on the shelf, priced out of reach,” Gayle Pledger, part of organizations Just Treatment and Right to Breathe, said in a statement.“Today, that changes,” she continued. “[W]e’ve proven that patient power can change what billion-dollar corporations refuse to. Governments must act fast to take all the necessary steps to make this lifesaving drug available for every eligible patient.”This is hardly the first time Vertex has taken flak over the availability of its CF meds, and the company had a previous run-in with the buyers club in 2019 over an earlier combo therapy, according to Stat News.In that instance, the group elected to work with Argentinian drugmaker Gador to produce a cheaper generic of Vertex’s Trikafta predecessor Orkambi, which weds the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator ivacaftor with the CFTR corrector lumacaftor. Meanwhile, a paper published in The Journal of Cystic Fibrosis in 2022 argued that while Vertex’s arsenal of CFTR modulator drugs has the “unparalleled opportunity to increase quality and length of life for almost all CF patients,” the therapeutics are “so expensive they are essentially unavailable unless reimbursed by the government or health system authorities.”That paper, which had the same lead author who penned the studies cited in the buyers club press release, estimated that just 12% of some 162,000 people thought to have CF worldwide were receiving Trikafta.The company's access agenda again came under fire in 2023, when a coalition of CF patients and families, helmed by Vertex Save US and the U.K.’s Just Treatment, petitioned governments in South Africa, Brazil, India and Ukraine to either revoke or suspend Trikafta patents. Outside the U.S., Trikafta goes by the name Kaftrio.

Drug Approval

100 Deals associated with Tezacaftor

External Link

KEGG	Wiki	ATC	Drug Bank
D11041	Tezacaftor	R07AX31	DB11712

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cough	Phase 3	Spain	Vertex Pharmaceuticals, Inc.	30 Jul 2021
Glucose Metabolism Disorders	Phase 3	Netherlands	Vertex Pharmaceuticals, Inc.	09 Nov 2020
Cystic Fibrosis	Phase 3	Netherlands	Vertex Pharmaceuticals, Inc.	08 Apr 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2025	Not Applicable	-	-	Elexacaftor	lstpopoitl(yypweqvrqc) = ofwxyzwjna leggdtlbdt (kozhhphcla )	-	16 May 2025
				Tezacaftor	lstpopoitl(yypweqvrqc) = lrwfdbfbec leggdtlbdt (kozhhphcla )
SKYLINE 102，SKYLINE 103 (NEWS)	-	Cystic Fibrosis	971	Vanzacaftor+替扎卡托+氘代艾伐卡托Vanzacaftor+替扎卡托+氘代艾伐卡托	ipvaveyjea(wzhpateybr) = 与安慰剂对比，使更多患者免于长期严重残疾 vivpcbxyvl (vmfhgcqclk ) View more	Positive	05 Feb 2024
				艾伐卡托+替扎卡托+Elexacaftor艾伐卡托+替扎卡托+Elexacaftor
ERS2023	Not Applicable	Cystic Fibrosis	156	Elexacaftor, Tezacaftor and Ivacaftor (ETI)	aracrkrryn(vlekbchnkn) = btylfytdmg zzauomhknc (vsgxksrvxf ) View more	Positive	09 Sep 2023
ERS2023	Not Applicable	Cystic Fibrosis	15	Elexacaftor/Tezacaftor/Ivacaftor (ETI)	osclxgjrzn(iukadxdrar) = felbjpfbmy jjmkertnoh (jxkhqqlqjg )	Positive	09 Sep 2023
ERS2023	Not Applicable	Cystic Fibrosis	45	Elexacaftor/Tezacaftor/Ivacaftor (ETI)	nhfuvypkac(nqsiwbsjmw) = One patient was diagnosed with bipolar disorder wnzzgslkbu (iqxfchuibm ) View more	Negative	09 Sep 2023
ERS2023	Not Applicable	Cystic Fibrosis	50	Elexacaftor/Tezacaftor/Ivacaftor	itohljzddm(juyxnngnef) = Patients with a low pre-treatment RV/TLC ratio showed higher responses after 12 months of ETI pirzutthgg (qbozeowftb )	Positive	09 Sep 2023
				Placebo
NCT02953314 (CTgov)	Phase 3	Cystic Fibrosis	83	IVA+TEZ (Part A)	yiauzlfbqy(cmhtqmjdka) = yjbppdopza xzvebimvyr (dkulxssahx, 10.3) View more	-	05 Dec 2019
				IVA+TEZ/IVA (Part B)	beaxlvfhsy = ztzwmkbddb xqwrkbygxn (fzmlmxdaux, vvkxjxwxif - ujefcojbzt) View more
NCT02953314 (Pubmed) Manual	Phase 3	Cystic Fibrosis	70	tezacaftor in combination with ivacaftor	zzeqecaxui(mcztmlseke) = bupilwzkpm fylfmzwcyy (zkfkezwyqw )	Positive	01 Sep 2019
NCT02070744 (CTgov)	Phase 2	Cystic Fibrosis	40	Ivacaftor+VX-661 (PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h)	tnrchanrsf = nztbfnlyur kjllfiioub (clkdlniwad, zdqwrimnqc - fjyowbpngv) View more	-	13 Apr 2018
				Ivacaftor+VX-661 (PC Phase: VX-661 100 mg qd + IVA 150 mg q12h)	tnrchanrsf = tvgvnzwlof kjllfiioub (clkdlniwad, yegdgqaeeu - yyptcoekhv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis